Advances in Cancer Therapy Resistance
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 2461
Special Issue Editor
Interests: novel target identification & validation; cell signaling networks; cancer therapy resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Drug resistance is the main therapeutic obstacle to developing cancer cures and dampens the clinical efficacy of a wide range of anti-cancer therapies, such as radiation, cytotoxic chemotherapies, molecular targeted therapies and immune checkpoint inhibitors. Different genetic, epigenetic and microenvironmental changes promote therapy resistance in tumor cells. Although combination therapy works well to overcome resistance to single-agent treatments in certain human malignancies, de novo and acquired resistance to combination therapies is common, especially in patients with metastatic disease, preempting the initial success of combinational therapies and resulting in disease relapse. Therefore, a deep apprehension of the molecular mechanisms underlying cancer therapy resistance is necessary to improve current therapies and pave the way for novel and more effective future cancer treatments. In this Special Issue, the latest findings on the distribution of genetic, epigenetic and microenvironmental mediators of cancer therapy resistance will be outlined. Moreover, novel treatment methods for overcoming therapy failure in in vitro, in vivo and preclinical models are of particular interest. Research articles, reviews and communications will all be considered for publication in this Special Issue.
Dr. Majid Momeny
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy resistance
- genetic mutations in drug resistance
- tumor microenvironment and therapy resistance
- epigenetic mediators in drug resistance
- cell signaling pathways in therapy failure
- combination therapies
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: To be determined
Authors: Mateusz Psurski; et al.
Affiliation: Laboratory of Experimental Anticancer Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland
